$7.8B Gilead Arcellx Merger: What It Means for CAR-T Cancer Therapy Market
U.S.-based biopharmaceutical giant Gilead Sciences has announced a definitive agreement to acquire cancer therapy developer Arcellx for approximately…
U.S.-based biopharmaceutical giant Gilead Sciences has announced a definitive agreement to acquire cancer therapy developer Arcellx for approximately…